Novo Nordisk CEO States the Company is Actively Pursuing Deals to Strengthen Its Pipeline
Novo Nordisk CEO Mike Doustdar stated the company is more active than ever in seeking business development opportunities and acquisitions to expand its pipeline. The comments come amid growing competition in the obesity drug market, where rival Eli Lilly has gained market share in weekly GLP-1 shots, though Novo leads in GLP-1 pills.
Topics: Competitive Landscape GLP-1 Drugs M&A Pharmaceuticals Pipeline Development